Respironics
New Product Introduction:

CAPNOSTAT® 5 Mainstream CO_2 Sensor for Use with Philips Medical Systems Patient Monitors

Respironics is pleased to announce that we have signed a new OEM Agreement for our CO_2 technologies with Philips Medical Systems. Philips Medical Systems will incorporate the new CAPNOSTAT 5® Mainstream CO_2 technology into their Intellivue family of Patient Monitors. Philips plans to begin promoting the product at the National Teaching Institute (NTI) show being held in New Orleans, LA on May 10th.

Respironics developed CAPNOSTAT 5 as the next generation in CO_2 technology for use during anesthesia, recovery, in the intensive care unit (ICU), and in emergency medicine/transport or respiratory care. Easily integrated with virtually any patient monitoring system, the CAPNOSTAT 5 Sensor provides technologically advanced measurement of End-Tidal Carbon Dioxide ($ETCO_2$) and respiration rate, as well as a clear, accurate capnogram at respiratory rates of up to 150 breaths per minute. Designed for mainstream sampling, the CAPNOSTAT 5 uses sophisticated infrared absorption spectroscopy to measure $ETCO_2$ directly at the patient's airway so response time is faster and there is less chance for erroneous data.

Respironics has provided innovative and cost-effective products to its OEM partners for over 15 years. We are dedicated to assisting our OEM customers in the successful implementation of state-of-the-art respiratory monitoring technology designed to meet the needs of their customers.

According to Philip Nuzzo, Respironics Hospital Division, Vice President, OEM and Business Development, "CAPNOSTAT 5 is an exciting start to a new generation of products, and we look forward to the beginning of an ongoing business relationship with Philips Medical Systems. The success of this product is closely tied to the continuing success of our OEM customers, and Respironics is excited to add Philips to this growing list of customers.